Quantbot Technologies LP Invests $2.22 Million in Supernus Pharmaceuticals, Inc. $SUPN

Quantbot Technologies LP bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 47,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,219,000.

Several other hedge funds and other institutional investors have also made changes to their positions in SUPN. BlackRock Inc. purchased a new position in Supernus Pharmaceuticals in the second quarter valued at about $434,871,000. State Street Corp lifted its stake in shares of Supernus Pharmaceuticals by 1.4% during the fourth quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after purchasing an additional 31,668 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after buying an additional 62,875 shares during the period. Loomis Sayles & Co. L P boosted its position in shares of Supernus Pharmaceuticals by 12.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock worth $72,007,000 after buying an additional 162,905 shares during the period. Finally, Stephens Investment Management Group LLC grew its stake in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after buying an additional 61,120 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $45.11 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68. The stock’s 50-day simple moving average is $46.77 and its 200-day simple moving average is $48.80. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of -23.49, a PEG ratio of 0.85 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business had revenue of $219.06 million during the quarter, compared to analysts’ expectations of $205.31 million. During the same period in the prior year, the company posted $0.40 EPS. The company’s revenue for the quarter was up 32.4% on a year-over-year basis. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.